July 2, 2014
  • Study Finds Low Cardiac Risks With Antidepressant
    Use in Pregnancy

    Pharmacists can share some good news with expectant mothers: A recent study found that taking antidepressants did not increase cardiac malformations in the first trimester. A second study involving animal research raises some troubling questions, however, about the link between use of the most common depression medications and heightened risk of obesity and diabetes for the unborn child. Here are the details.

  • Risks, Benefits Found for Thrombolytic Therapy in Pulmonary Embolism

    When do the benefits of using thrombolytic therapy in pulmonary embolism outweigh the risks? That is the question researchers sought to answer in a new study that found the therapy lowered death rates but also causes increased risks of major bleeding and intracranial hemorrhage. Find out what the authors had to say about optimal usage.

  • New Warning for “Low T” Therapy Involves VTE Risks

    The FDA announced in January that it is looking at the possible link between testosterone therapy and increased risks of stroke, heart attack, and death. Yet the agency insists its latest mandate for a label change is unrelated. What prompted the FDA to revise guidance on the risk of venous thromboembolism (VTE) with “Low T” therapy?

  • Sulfonylurea Preferable to Insulin As Diabetes
    Therapy Add-On

    The last few years have seen a big push for earlier initiation of insulin in patients with type 2 diabetes. A new study suggests why that might not be a good idea. How did adding insulin instead of a sulfonylurea to diabetes treatment affect cardiovascular outcomes and the overall death rate?


U.S. Pharmacist Social Connect